CIPLA LTD. - 500087 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to regulation 74(5) of SEBI (DP) regulations, 2018, we enclose herewith a copy of the certificate received from Kfin Technologies Limited, the Registrar and Share Transfer Agent of the Company CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 25th January 2024.
Cipla Unit To Develop Cell Therapy Products In JV With Kemwell, Manipal
The strategic collaboration is aimed at expediting development, manufacturing, licensing, import and export of cutting-edge cell therapy products. CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative cell therapy products CIPLA LTD. - 500087 - Update On The Definitive Agreement Entered Between Cipla Technologies LLC And Pulmatrix Inc. For Development And Commercialization Of Pulmazole
Update on the Definitive Agreement entered between Cipla Technologies LLC and Pulmatrix Inc. for development and commercialization of Pulmazole CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Acquisition
Cipla (EU) Limited, wholly owned subsidiary of the Company in UK, has entered into a joint venture agreement with Kemwell Biopharma UK Limited and MNI Ventures, Mauritius on 5th January, 2024 for incorporation of a joint venture company in USA. CIPLA LTD. - 500087 - Board Meeting Intimation for Quarter And Nine Month Ended 31St December 2023
CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2024 ,inter alia, to consider and approve Pursuant to regulation 29 of listing regulations, we wish to inform you that the meeting of the board of directors of the company will he held on Thursday, 25th January, 2024 interalia to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended 31st december 2023. CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 of SEBI Listing Regulations, 2015, we hereby notify that the operations and administrative committee of the company on 2nd January 2024, has allotted 7,244 fully paid-up equity shares of INR 2 each, pursuant to exercise of employee stock options /stock appreciation rights under the Employee Stock Option Scheme 2013 A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company. Consequently, the issued, subscribed and paid-up capital of the Company stands increased to 1,61,47,15,284 comprising of 80,73,57,642 equity shares of face value INR 2 each. CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.